After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
Monday, Addex Therapeutics (NASDAQ:ADXN) announced its partner Janssen Pharmaceuticals, Inc, a unit of Johnson & Johnson (NYSE:JNJ), has discontinued the development of ADX71149 (JNJ-40411813) in epilepsy.
周一，Addex Therapeutics（纳斯达克：ADXN）宣布其合作伙伴强生（Johnson & Johnson）子公司Janssen Pharmaceuticals，Inc停止开发ADX71149（JNJ-40411813）用于癫痫的治疗。
The partnership between the two companies remains ongoing while the full data set from the Phase 2 study of ADX71149 (JNJ-40411813) as an adjunctive epilepsy treatment is analyzed.
两家公司的合作关系仍在继续，而ADX71149(JNJ-40411813)作为辅助癫痫治疗方法的二期研究的全部数据集正在分析中。
The decision follows top-line Phase 2 data announced in April, showing that adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.
决定是在四月份公布的一期数据后作出的，该数据显示，在仅对使用了levetiracetam或brivaracetam的患有局限性发作的患者进行辅助治疗的情况下，ADX71149添加到病人的护理标准后，未能达到病人达到基线癫痫计数所需的时间主要指标的统计学意义。
After the data, Addex Therapeutics stock tumbled almost 50%.
在数据公布后，Addex Therapeutics的股价下跌了近50％。
"Following the Phase 2 study results in epilepsy, this decision was anticipated. We have had an excellent working relationship with Janssen for twenty years and will continue to work diligently to complete the analysis of the full Phase 2 data set to elucidate all learnings from the study," said Tim Dyer, CEO of Addex. "Once we have that information in hand, we anticipate a decision on the future of this asset."
“在癫痫二期研究结果公布后，这个决定是可以预见的。我们与Janssen有着20年的良好工作关系，并将继续努力完成全面的二期数据集分析，以阐明该项研究的所有学习成果，”Addex的CEO Tim Dyer说：“一旦我们掌握了这些信息，我们就会对该资产的未来做出决策。”
Price Action: ADXN stock is down 1.36% at $7.99 during the premarket session at last check Monday.
股票价格行情：截至周一早盘，ADXN股票价格为7.99美元，下跌1.36％。
- Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications.
- 疯狂追逐用于减肥的Ozempic和Zepbound导致糖尿病患者无法使用关键的GLP-1药物。